V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005891 | 330012292 | 1.71 | 67.8 | Adjuvant (A) | 2014-09-08 | 2014-09-09 | PCV | Y | N | 330004588 | MELPHALAN |
| 330005892 | 330012292 | null | 62.1 | Palliative (P) | null | 2014-05-06 | GEMCITABINE | N | N | 330004588 | CHLORAMBUCIL |
| 330005893 | 330012292 | 1.62 | 10.6 | null | 2017-02-07 | 2017-03-02 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | N | N | 330004588 | CARBOPLATIN + RT |
| 330005894 | 330012292 | null | 54 | Palliative (P) | 2015-06-21 | 2015-07-06 | FLAG + Idarubicin | N | N | 330004588 | CVD (NEUROENDOCRINE) |
| 330005895 | 330002795 | 1.61 | 67 | Adjuvant (A) | 2015-02-11 | 2015-02-15 | PEMBROLIZUMAB | N | N | 330004942 | DOXORUBICIN + OLARATUMAB |
| 330005896 | 330002795 | 1.67 | 0 | Curative (C) | 2015-11-02 | 2015-11-20 | AML17 TRIAL | N | N | 330004942 | AML17 TRIAL |
| 330005897 | 330010093 | 1.87 | 68.5 | Palliative (P) | 2015-09-17 | 2015-09-24 | HCX (Cape + Cisp + Tras) - Load | 02 | Y | 330005099 | ETOPOSIDE + IFOSFAMIDE |
| 330005898 | 330011515 | 1.7 | 62.5 | Curative (C) | 2015-12-16 | 2015-12-16 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 2 | N | 330005116 | VINBLASTINE |
| 330005899 | 330011515 | 1.6 | 19.7 | Curative (C) | 2017-04-08 | 2017-04-26 | CHLORAMBUCIL + OFATUMUMAB | 02 | N | 330005116 | CAPECITABINE + CARBOPLATIN |
| 330005900 | 330002796 | null | 59.4 | Palliative (P) | 2018-02-15 | 2018-03-03 | FLAG + Idarubicin | N | N | 330005191 | CISPLATIN + FLUOROURACIL + RT |
| 330005901 | 330002797 | 0.9 | 83.6 | Disease modification (D) | 2018-01-30 | 2018-01-30 | CAPECITABINE + CARBOPLATIN + Cetuximab | 2 | N | 330005204 | ICE |
| 330005902 | 330002798 | null | 0 | Palliative (P) | 2016-09-14 | 2016-09-15 | RUXOLITINIB | 02 | N | 330005236 | GEMCITABINE |
| 330005903 | 330002799 | 1.72 | null | null | 2017-01-03 | 2017-01-03 | Cisplatin + Fluorouracil + RT 5day | 2 | N | 330005401 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005904 | 330002799 | null | 52.8 | Adjuvant (A) | 2018-09-10 | 2018-09-30 | METHOTREXATE | N | null | 330005401 | DOCETAXEL + GEMCITABINE |
| 330005905 | 330002799 | null | null | Adjuvant (A) | null | 2019-02-13 | Gemcitabine day 1&8 | N | N | 330005401 | CISPLATIN + DOCETAXEL |
| 330005906 | 330002800 | 0 | 97.3 | null | null | 2017-07-31 | Carboplatin + Docetaxel | null | null | 330005504 | CISPLATIN + VINORELBINE |
| 330005907 | 330002801 | 0 | 60 | Curative (C) | 2015-07-23 | 2015-07-23 | Chlorambucil | 02 | N | 330005550 | DOCETAXEL + GEMCITABINE |
| 330005908 | 330002802 | 1.64 | 44 | Curative (C) | 2017-05-29 | 2017-05-30 | FLUOROURACIL + MITOMYCIN | N | N | 330005572 | VINBLASTINE |
| 330005909 | 330007523 | null | 80 | Disease modification (D) | 2018-08-23 | 2018-08-24 | Pazopanib | null | null | 330005707 | CLADRIBINE |
| 330005910 | 330007523 | 1.67 | 53.9 | Adjuvant (A) | null | 2018-04-05 | CHOP R - 21 days | N | N | 330005707 | AML16 TRIAL |
| 330005911 | 330007523 | 1.63 | 111.8 | Curative (C) | 2015-03-25 | 2015-03-29 | Gemcitabine + Treosulfan (po) | 02 | N | 330005707 | CISPLATIN + ETOPOSIDE + RT |
| 330005912 | 330007523 | 1.82 | 75.8 | Neo-adjuvant (N) | 2017-07-07 | 2017-07-07 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 02 | null | 330005707 | EVEROLIMUS |
| 330005913 | 330002803 | 0 | 85.7 | Neo-adjuvant (N) | 2016-08-03 | 2016-10-18 | Azacitidine | 2 | N | 330005788 | DABRAFENIB |
| 330005914 | 330007524 | null | 61 | Palliative (P) | 2017-03-28 | 2017-04-05 | CREATE TRIAL | N | N | 330006106 | EMA/CO |
| 330005915 | 330010096 | 1.65 | 83.2 | Palliative (P) | 2018-05-24 | 2018-06-07 | IMATINIB | N | Y | 330006301 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005916 | 330010096 | 1.55 | null | Palliative (P) | null | 2016-12-07 | TEMOZOLOMIDE | N | N | 330006301 | FLAG + IDARUBICIN |
| 330005917 | 330002804 | 1.62 | 67.4 | Curative (C) | 2015-05-20 | 2015-06-01 | Etoposide + Ifosfamide (3 days) | N | N | 330006361 | BEP |
| 330005918 | 330002804 | 1.63 | 103.4 | null | 2013-04-29 | 2013-05-02 | FEC + DOCETAXEL | 1 | null | 330006361 | ECX |
| 330005919 | 330002805 | 0 | 68.5 | Palliative (P) | 2017-12-25 | 2017-12-25 | Capecitabine + Cisplatin | N | N | 330006640 | CETUXIMAB + CISPLATIN + FU |
| 330005920 | 330002806 | 1.77 | 70 | Palliative (P) | 2017-11-30 | 2017-12-26 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330006669 | ENZALUTAMIDE |
| 330005921 | 330002806 | 0 | 78 | Palliative (P) | 2017-06-19 | 2017-06-20 | Midostaurin | N | N | 330006669 | EDP + MITOTANE |
| 330005922 | 330002806 | 1.55 | 49 | Palliative (P) | 2017-05-24 | 2017-05-27 | EDP | N | N | 330006669 | CAPECITABINE + CARBOPLATIN |
| 330005923 | 330002807 | 0 | 86 | Palliative (P) | 2016-09-02 | 2016-09-15 | Azacitidine | 02 | N | 330006932 | FLAG + IDARUBICIN |
| 330005924 | 330002808 | 1.71 | 100.5 | Curative (C) | 2017-02-01 | 2017-03-01 | CAPECITABINE + OXALIPLATIN | N | N | 330007106 | TEMOZOLOMIDE |
| 330005925 | 330002808 | null | 76.1 | null | 2016-05-07 | 2016-05-07 | Bortezomib + CYCLOPHOSPHAMIDE | N | null | 330007106 | TEMOZOLOMIDE |
| 330005926 | 330002808 | null | 79 | Curative (C) | 2016-08-03 | 2016-08-07 | OCTREOTIDE | N | null | 330007106 | BENDAMUSTINE |
| 330005927 | 330011518 | null | null | Curative (C) | 2018-01-21 | 2018-01-21 | CVP | N | N | 330007248 | PAZOPANIB |
| 330005928 | 330011518 | 1.64 | 52 | Palliative (P) | 2017-03-12 | 2017-03-12 | EDP + MITOTANE | N | N | 330007248 | AML19 TRIAL |
| 330005929 | 330011518 | 1.69 | 83.5 | Palliative (P) | 2017-10-20 | 2017-10-22 | RUXOLITINIB | N | N | 330007248 | CAV |
| 330005930 | 330011518 | null | 12.3 | Palliative (P) | 2017-07-08 | 2017-07-08 | AML Int Guide ADE 10+3+5 (1) | Y | N | 330007248 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 330005931 | 330002809 | 1.62 | 58.1 | Curative (C) | null | 2014-12-03 | UKALL XII Induction Phase 1 | null | null | 330007592 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330005932 | 330002809 | 1.75 | 74.8 | Curative (C) | 2018-05-30 | 2018-06-03 | AML 18 TRIAL | 02 | N | 330007592 | POMB |
| 330005933 | 330010099 | 1.7 | 85.7 | Palliative (P) | 2018-07-09 | 2018-07-20 | BEP 5 Day | 02 | N | 330007632 | CYCLOPHOSPHAMIDE |
| 330005934 | 330010099 | null | 71.2 | null | 2016-04-03 | 2016-04-03 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | N | Y | 330007632 | CYTARABINE |
| 330005935 | 330010099 | 1.73 | 78.3 | Palliative (P) | null | 2016-03-21 | Chlorambucil + Pred + Rituximab | N | N | 330007632 | AML18 TRIAL |
| 330005936 | 330010099 | 1.67 | 43 | Adjuvant (A) | 2018-08-27 | 2018-09-27 | Temozolomide + RT | N | N | 330007632 | MIFAMURTIDE |
| 330005937 | 330002810 | 0 | 11 | Curative (C) | 2018-12-09 | 2018-12-18 | Azacitidine | N | N | 330007777 | CARBOPLATIN + DOXORUBICIN |
| 330005938 | 330002811 | 1.7 | null | Palliative (P) | 2017-10-13 | 2017-10-13 | Mitotane 3 - 3.5g | 02 | N | 330008031 | IMATINIB |
| 330005939 | 330002812 | 1.68 | 51.5 | Palliative (P) | null | 2017-01-26 | Vincristine (weekly) | 2 | N | 330008201 | MITOTANE |
| 330005940 | 330007529 | 1.85 | 85 | Palliative (P) | 2018-05-18 | 2018-05-18 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 330008308 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |